Companies › Algernon Pharmaceuticals
1 active drug program in 2 registered trials: 1 Phase 1, 1 Phase 2; Neurology, Psychiatry.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| N,N-Dimethyltryptamine (DMT) Serotonin receptor agonist | – | Phase 1 | Stroke; MDD | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05559931 | N,N-Dimethyltryptamine (DMT) | Phase 1 | Stroke | Neurology | Mar 2026 |
| NCT07562191 | N,N-Dimethyltryptamine (DMT) | Phase 2 | MDD | Psychiatry | Feb 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.